Form 4: NovoCure Chief Human Resources Officer Acquires Shares Under Employee Purchase Plan

NovoCure Ltd.'s Chief Human Resources Officer, Michal Nath Puri, acquired 833 ordinary shares at $15.13 per share through the company's Employee Share Purchase Plan.

Summary

• Michal Nath Puri, NovoCure Ltd.'s Chief Human Resources Officer, acquired 833 ordinary shares.
• The shares were purchased at a price of $15.13 per share.
• The acquisition was made under the 2025 NovoCure Limited Employee Share Purchase Plan (ESPP).
• The purchase period for this transaction was January 1, 2025, through June 30, 2025.
• The purchase price of $15.13 was based on 85% of the closing price of NovoCure's ordinary shares on June 30, 2025.
• Following this transaction, Michal Nath Puri beneficially owns 164,514 ordinary shares.
• The transaction is exempt under Rule 16b-3(c).

Sentiment

Score: 7

Explanation: The acquisition of shares by a Chief Human Resources Officer, even through an ESPP, generally indicates a positive alignment of interests and confidence in the company. While not a direct open-market purchase, it still increases insider ownership.

Positives

• Insider acquisition of shares, indicating confidence in the company's future.
• Participation in an Employee Share Purchase Plan (ESPP) encourages employee alignment with shareholder interests.
• The purchase was made at a discounted price (85% of closing price), which is a benefit for the employee.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook, as it primarily reports an insider's share acquisition.

Management Comments

• The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025.
• In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2025.

Industry Context

This filing is specific to an individual insider's share acquisition and does not provide broader industry context or trends. It reflects an internal compensation and ownership structure rather than market-wide or competitive dynamics.

Comparison to Industry Standards

• This Form 4 filing does not contain information suitable for comparison to industry standards regarding financial performance or operational benchmarks. It details an individual's share acquisition under an employee plan, which is a common practice across various industries to align employee and shareholder interests.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively as it aligns management interests with shareholder value.
• Employees: The ESPP provides an opportunity for employees to acquire company shares at a discount, fostering a sense of ownership and potentially improving retention.

Next Steps

• Future ESPP purchase periods for employees.
• Subsequent Form 4 filings for any further changes in beneficial ownership by insiders.

Key Dates

Keywords

NovoCure, NVCR, Form 4, Insider Trading, Share Acquisition, Employee Stock Purchase Plan, ESPP, Michal Nath Puri, Chief Human Resources Officer, Beneficial Ownership